Skip to main content

Human IL-22 ELISA, High Sensitivity (Serum, Plasma, TCM)

Hero Region
Product Info

Matrix Compatibility Serum, Plasma, Tissue Culture Media
Assay Range

0.78 - 50 pg/ml

LLOQ

0.78 pg/ml

Need more sensitivity? Check out our Sample Testing Services

Assay Length 4 hours
Specificity Human IL-22

 

PBL’s IL-22 ELISA is intended for quantification of IL-22 in Tissue Culture Media (TCM), and complex matrices such as serum and plasma. The high-affinity form of the IL-22 binding protein (IL22-BP) does inhibit this assay which suggests the ELISA may measure free IL-22 in samples.

Specifications

CVs and Spike Recovery

Inter-Assay: < 10%


Intra-Assay: < 10%


Spike recovery: > 96%

Cross-reactivity

Limited cross-reactivity with

  • < 1% non-specific detection observed with monkey IL-22 (0.02% and 0.03% from two different runs)

 

No cross-reactivity detected with

  • Human IL-10, IL-17, IL-19, IL-20, IL-24, IL-26/AK155, IFN-β 1a, IFN-γ, IFN-ω
  • Cynomolgus IFN-α 2
  • Cynomolgus/rhesus IFN-α
  • Mouse IL-22, IFN-α A, IFN-β, IFN-γ
  • Rat IL-22, IFN-α 1, IFN-α 14, IFN-β, IFN-γ
  • Bovine IFN-Tau 2 or pig IFN-α.
Storage 2-8 °C
Expiration Date One year from the date of manufacture
Shipping Condition Wet Ice

 

Materials Provided

  • Pre-Coated Micro-Titer Stripwell Plate/Sealers
  • Wash Solution Concentrate
  • Human IL-22 Standard (10,000 pg/ml)
  • Standard Diluent
  • Assay Buffer
  • Antibody Concentrate
  • HRP Conjugate Concentrate
  • Concentrate Diluent
  • HRP Diluent
  • TMB Substrate Solution
  • Stop Solution

 

Additional Materials Required (Not Provided) 

  • Microplate reader capable of reading an OD at a wavelength of 450 nm
  • Variable volume microtiter pipettes
  • Adjustable multichannel pipette (50-300 μl)
  • Reagent reservoirs
  • Wash bottle or plate washing system
  • Distilled or deionized water
  • Serological pipettes (1, 5, 10 or 25 ml)
  • Disposable pipette tips (polypropylene)
  • Plate shaker

Tech Info & Data

 

Representative Standard Curve in Standard Diluent

Human IL-22 standard curves were prepared in Standard Diluent (SD) and assayed in triplicate over nine runs. The figure below shows the dose response and absorbance values. Error bars indicate the standard deviation.

 

 

Intra-Assay Precision

Sample 1 2 3 4
n 18 18 18 18
Mean (pg/ml) 26..68 6.42 2.86 4.52
Standard Deviation 1.38 0.62 0.16 0.18
CV (%) 5.2 9.7 5.5 4.1

 

 

 

 

Inter-Assay Precision

Sample 1 2 3 4 5
n 5 5 5 5 5
Mean (pg/ml) 28.05 6.73 3.13 4.80 5.79
Standard Deviation 3.62 0.68 0.17 0.27 0.54
CV (%) 12.9 10.1 5.3 5.7 9.3

 

 

Intermediate Precision

Sample 1 2 3 4 5
n 27 27 27 27 27
Mean (pg/ml) 31.93 7.76 3.43 5.30 6.45
Standard Deviation 4.34 1.24 0.24 0.62 0.94
CV (%) 13.6 16.0 12.3 11.8 14.6

 

Spike Recovery

TCM

Spike Sample 1 2 3
Target Conc. (pg/ml) 100 25 5
Mean Recovery 101.9 93.9 90.8
Range (%) 100.7-103.0 90.3-97.5 90.2-91.4

Disodium-EDTA Plasma

Spike Sample 1 2 3
Target Conc. (pg/ml) 100 25 5
Mean Recovery 97.3 88.7 83.9
Range (%) 87.6-102.6 82.0-93.3 76.1-92.5

Serum

Spike Sample 1 2 3
Target Conc. (pg/ml) 100 25 5
Mean Recovery 90.9 87.1 84.8
Range (%) 83.3-100.5 80.0-98.9 74.6-94.5

 

Representative Standard Curves in Various Matrices

 

Percent Recovery of IL-22 in Various Matrices

 

Parallelism of Normal Human Serum (NHS)

Three NHS samples with high levels of endogenous IL-22 were assayed in duplicate to assess reliable quantification after dilution within the standard curve range. Endogenous samples were diluted in Standard Diluent down to a 16-fold dilution. All samples fell within 100 ± 20% of the neat value. Error bars indicate the standard deviation.

 

Parallelism of Disease State Serum

Four Atopic Dermatitis (AD) serum samples with high levels of endogenous IL-22 were assayed in duplicate to assess reliable quantification after dilution within the standard curve range. Samples were diluted in Standard Diluent (SD) down to a 16-fold dilution. All samples fell within 100 ± 20% of the neat value. Error bars indicate the standard deviation.

 

Linearity of NHS

 

Linearity of Disodium-EDTA Plasma

 

Linearity of Na-Heparin Plasma

 

Representative Standard Curves of PBL and Competitor A

PBL’s and Competitor A’s standards were assayed on the 41701 PBL ELISA. Figure 13 shows the dose response curves and absorbance values in Standard Diluent (SD). Competitor A’s standard exhibits a lower dose response compared to PBL’s standard, as well as a lower percent recovery, which is less than 80% of the expected value. Competitor A’s standard curve demonstrated less sensitivity than PBL’s IL-22 ELISA.

 

Comparison of Percent Recovery Curves of PBL and Competitor A

Curves The figure below shows the recovery of the individual IL-22 standards at various concentrations. Competitor A’s standard was backfitted against PBL human cell-expressed standard, which was used to interpolate the concentrations of IL-22 and calculate the percent recovery of the curves from the expected value. PBL’s ELISA exhibited higher percent recovery than Competitor A.

 

PBL’s IL-22 ELISA (41701) Standard Curve in the Presence of IL22-BP

 

Competitor A’s Standard Curve in the Presence of IL22-BP

 

PBL’s IL-22 ELISA (41701) Recovery in the Presence of IL22-BP

 

Competitor A's Recovery in the Presence of IL22-BP

 

Healthy Donor Readability on PBL's ELISA

Sample Type Mean of Quantified (pg/ml) Range (pg/ml) % Quantified %Non-Quantified % CV
NHS 1.84 0.80 - 5.43

96

(23/24)

4 5.6
Sodium-Citrate Plasma 2.54 1.06 - 24.60

100

(7/7)

0 4.5

 

Healthy Donor Readability on Competitor A's ELISA

Sample Type Mean of Quantified (pg/ml) Range (pg/ml) % Quantified %Non-Quantified % CV
NHS 20.43 16.26 - 24.60

8

(2/24)

92 2.8
Sodium-Citrate Plasma ND ND 0 100 ND

ND: Not Detectable

 

Disease State Readability on PBL's ELISA

Sample Type Mean of Quantified (pg/ml) Range (pg/ml) % Quantified %Non-Quantified % CV
AD 14.77 2.30 - 32.18 100 0 2.1
Psoriasis 5.33

1.25 - 25.99

100 0 3.8
RA 5.58 1.98 - 9.47 100 0 3.7
SLE 3.13 1.55 - 9.22 100 0 4.7

 

Disease State Readability on Competitor A's ELISA

Sample Type Mean of Quantified (pg/ml) Range (pg/ml) % Quantified %Non-Quantified % CV
AD 32.42 14.28 - 73.07 60 40 5.0
Psoriasis 33.09 N/A 10 90 2.9
RA ND ND 0 100 ND
SLE ND ND 0 100 ND

 

Background

 

IL-22 is a member of the IL-10 family of cytokines1. Other names include IL-TIF and Zcyto18. IL-22 is produced by a variety of cells including Th1, Th17, Th22 T-cells, NKT cells, ILC3, neutrophils and macrophages2.  Targeting primarily non-hemopoietic cells such as stromal and epithelial cells, IL-22 exerts both protective effects, such as hepatocyte and epithelial cell survival, and pro-inflammatory effects. It is also implicated in autoimmune diseases such as Systemic Lupus Erythematosus, Rheumatoid Arthritis and Psoriasis3. IL-22 is often considered a hallmark of IL-17 driven immune responses4.

Citations

References:

 

  1. Dumoutier, L., et al. 2000. Genes & Immunity.  1(8): 488-94.

  2. Dudakov J., Hanash A., van den Brink, M. 2015. Annual Review of Immunology. 33: 747-785.

  3. Eyerich, K., Dimartino, V., Cavani, A. 2017. European Journal of Immunology. 47(4): 607-614.

  4. Eyerich, S., et al. 2017. Allergologie Select. 1(1): 71-76.

Documentation

Certificate of Analysis (CoA) & Protocol, Technical Data Sheet (TDS), Safety Data Sheet (SDS)
41701 Performance Characterization Study Poster

41701 Performance Characterization Study Poster

41701-1 CoA & Protocol (One-Page)

41701-1 Certificate of Analysis (CoA) & Protocol (One-Page)

41701-1 Technical Data Sheet

41701-1 Technical Data Sheet

41701 SDS

41701 Safety Data Sheet

41701 Product Flyer

41701 Product Flyer